StockData

agilon health vs Progyny

AGL and PGNY side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AGL and PGNY compare

Progyny is the larger company, worth 1.4 times as much as agilon health ($2.8B against $1.9B).

Progyny grew revenue faster over the last twelve months (5.5% versus 2.0% for agilon health).

Progyny keeps more of each dollar of sales as profit, with a net margin of 6.8% compared with −1.5% at agilon health.

Progyny scores higher on the StockData Score (21 against 4 for agilon health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAGLPGNY
Size and price
Market cap$1.9B$2.8B
Share price$115.66$36.18
Change, 1 year637%50.3%
Change, 5 years−80.5%−39.0%
Beta (5Y)1.281.06
Employees856856
StockData Score
Total score421 (better)
Valuation score13 (better)
Growth score16 (better)
Performance score16 (better)
Health score16 (better)
Dividend score00
Valuation
P/E–33.2×
P/S0.3× (better)2.1×
P/B–6.7×
EV/EBITDA–19.5×
P/FCF–15.5×
PEG–1.13
FCF yield−0.88%6.5% (better)
Fair value–$38.02
Margin of safety–4.8%
Growth
Revenue growth (TTM)2.0%5.5% (better)
Revenue growth, 5Y average37.2% (better)30.2%
Net income growth (TTM)–60.9%
EPS growth (TTM)–73.0%
EPS growth, 5Y average–6.7%
Profitability
Gross margin–24.9%
Operating margin−2.6%9.4% (better)
Net margin−1.5%6.8% (better)
FCF margin−0.28%13.4% (better)
Return on equity–18.7%
Return on invested capital–40.0%
Financial health
Debt / equity–0.00
Interest coverage−22.4×–
Current ratio1.131.93 (better)
Altman Z-score2.879.94 (better)
Piotroski F-score28 (better)
Dividends and buybacks
Buyback yield–11.3%
Shareholder yield0.00%11.3% (better)
Ownership
Held by institutions95.8%103%
Held by insiders10.1%2.6%
Insider net buying, 12 months$300K (better)−$23.9M
Superinvestors holding1–
Short interest, % of float5.6%6.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.